AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03815539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate
Description: In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
Study NCT04562467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]
Description: 2 x 1g capsules BID as per REDUCE-IT
Study NCT03645590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Ready
Description: Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
Study NCT02869607 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT01944033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bricanyl/Iprovent
Description: 5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
Study NCT01944033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bricanyl
Description: 5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
Study NCT04509869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: varicocelectomy
Description: operation for varix ligation
Study NCT02633501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P03277
Description: Single intravenous (IV) bolus injection at a rate of 2 mL/second
Study NCT02633501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Single IV bolus injection at a rate of 2 mL/second
Study NCT05784948 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Experience relaxing scenery and music
Description: once a week for 30 minutes, over 8 weeks
Study NCT01219855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 2 Matching Sugar Capsule
Description: Placebo capsules given once daily for 42 days.
Study NCT02592837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible 19G EBUS-TBNA needle
Study NCT02592837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 21G EBUS-TBNA needle
Study NCT01670019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5-20 mg daily
Description: 5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
Study NCT01831557 — intervention group
Intervention type: OTHER
Intervention: Blood samples will be taken for gene sequencing
Study NCT01670019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1-4 tablets daily
Description: One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
Study NCT02041546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lung lavage with surfactant
Study NCT02041546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus surfactant
Study NCT04286412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonacog alfa
Description: Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Study NCT04833985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation
Description: Each patient received the same group of patients with simple radiofrequency ablation and LAAC
Study NCT04187157 — intervention group
Intervention type: DEVICE
Intervention: Blue-light filtering intraocular lens
Description: Bilateral implantation of blue light-blocking intraocular lens
Study NCT02993224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox dispersable tablet (DT)
Description: Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water.
Study NCT04187157 — intervention group
Intervention type: DEVICE
Intervention: Conventional intraocular lens
Description: Bilateral implantation of conventional intraocular lens
Study NCT02993224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox film coated tablet (FCT)
Description: Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree).
Study NCT02917187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study NCT03966547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018
Description: Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
Study NCT03966547 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ganglion sphenopalatine block with placebo administered on study GSPB-2018
Description: Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
Study NCT02758821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No CRP will be measured onsite
Description: No CRP will be measured onsite
Study NCT02758821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CRP cut-off of 20mg/L.
Description: Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.
Study NCT02758821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CRP cut-off of 40mg/L.
Description: Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
Study NCT02917187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT02920684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive legs mobilisation
Description: A physiotherapist performs a passive leg movement
Study NCT01506726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
Study NCT01506726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
Study NCT00839579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1x4 min interval
Description: Aerobic interval training
Study NCT02920684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive cycloergometer
Description: A motorised cycloergometer performs a passive cycling
Study NCT02920684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscular electrical stimulation
Description: A neuromuscular electrical stimulation device performs a quadriceps located stimulation
Study NCT03135067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of multiple self-tests
Description: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
Study NCT04198402 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological sampling
Description: Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
Study NCT02955290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02955290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02955290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02955290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Description: Given CIMAvax IM
Study NCT04275284 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCV10
Description: 0.5 ml injection
Study NCT04275284 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCV13
Description: 0.5 ml injection
Study NCT04416958 — intervention group
Intervention type: DEVICE
Intervention: cardiac implantable electronic device (CIED) implantation
Description: CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
Study NCT02920684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES cycling
Description: A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
Study NCT04352634 — intervention group
Intervention type: OTHER
Intervention: Exposure to the SARS-CoV-2 and its consequences
Description: This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
Study NCT02487849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: secondary cytoreductive operation
Study NCT02487849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
Study NCT01669369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
Study NCT01669369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
Study NCT03186404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg OD
Study NCT03186404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT03160404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: The ZOLPIDEM group will be treated with zolpidem 10mg/night
Study NCT03160404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
Study NCT00804193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Topical Suspension
Description: topical suspension
Study NCT00804193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox Topical Suspension 0.77%-Reference Product
Description: topical suspension
Study NCT00804193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclopirox Olamine Topical Suspension-Placebo
Description: topical suspension
Study NCT01647594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YWI
Description: The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
Study NCT01647594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
Study NCT02557971 — intervention group
Intervention type: DRUG
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
Study NCT01596075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
Study NCT01167036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FascialEdge instrument
Description: Stroking massage to patient tolerance over the muscle
Study NCT03863574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2mg
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
Study NCT03863574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4mg
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
Study NCT03863574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Study NCT03884257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux treatment group
Description: Percutaneous endovascular angioplasty with the Passeo-18 lux
Study NCT01167036 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo electric point stimulation
Description: Detuned electric point stimulation over the involved muscle
Study NCT04511650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Razuprotafib Subcutaneous Solution
Description: Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
Study NCT03884257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IN.PACT Admiral treatment group
Description: Percutaneous endovascular angioplasty with the IN.PACT Admiral
Study NCT04171895 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
Study NCT04171895 — intervention group
Intervention type: OTHER
Intervention: Communication training Part 1 (no longer recruiting)
Description: 1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
Study NCT04171895 — intervention group
Intervention type: OTHER
Intervention: Enhanced usual care
Description: Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants.
Study NCT04171895 — intervention group
Intervention type: OTHER
Intervention: Communication training Part II
Description: Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
Study NCT04832698 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT03985527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvenous nerve stimulation
Description: Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
Study NCT04511650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous Solution
Description: Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
Study NCT01571037 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled, nebulized, Milrinone
Description: 1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
Study NCT01083862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention - Text plus DVD/VHS
Description: In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level.
Study NCT01083862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention - Text Only
Description: In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level.
Study NCT00442351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asmanex twisthaler
Description: Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
Study NCT00442351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Asmanex twisthaler
Description: Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
Study NCT00491257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
Description: 0.5 mL, Intramuscular
Study NCT00894933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTINUUM™
Description: Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.